Your session is about to expire
← Back to Search
Tailored message for Colorectal Cancer
N/A
Waitlist Available
Led By Michael L Kochman, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 120 days
Awards & highlights
Study Summary
This trial will test whether sending patients tailored messages before their colonoscopy will increase the chance that they will follow their provider's recommendations.
Eligible Conditions
- Colorectal Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 120 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Colonoscopy completion rate
Secondary outcome measures
Colonoscopy scheduling rate
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Tailored MessageExperimental Treatment1 Intervention
Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a "tailored" message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions.
Group II: Generic MessageExperimental Treatment1 Intervention
Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a "generic" message encouraging colonoscopy scheduling.
Group III: Usual CareActive Control1 Intervention
Participants in this arm will Usual scheduling process without any intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Generic message
2017
N/A
~600
Tailored message
2021
N/A
~1550
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,018 Previous Clinical Trials
42,873,532 Total Patients Enrolled
Michael L Kochman, MDPrincipal InvestigatorUniversity of Pennsylvania
2 Previous Clinical Trials
705 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had colorectal cancer in the past.You are not able to speak English.You have severe memory loss or other signs of dementia.You are currently pregnant.Your family has a history of inherited colorectal cancer syndromes like FAP or HNPCC.You are between 50 and 75 years old.You have a history of inflammatory bowel disease such as Crohn's disease or Ulcerative colitis.You experienced symptoms related to colorectal cancer, such as bleeding from your lower digestive tract, within the last 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: Usual Care
- Group 2: Generic Message
- Group 3: Tailored Message
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger